Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study.
Elkrief L, Bastien G, McAnulty C, Bakouni H, Hébert FO, Socias ME, Le Foll B, Lim R, Ledjiar O, Marsan S, Brissette S, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Elkrief L, et al. Among authors: bakouni h. J Subst Use Addict Treat. 2023 Jun;149:209031. doi: 10.1016/j.josat.2023.209031. Epub 2023 Mar 30. J Subst Use Addict Treat. 2023. PMID: 37003540 Free article. Clinical Trial.
Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study.
Bakouni H, Haquet L, Socias ME, Le Foll B, Lim R, Ahamad K, Jutras-Aswad D; OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse. Bakouni H, et al. J Addict Med. 2024 Mar-Apr 01;18(2):167-173. doi: 10.1097/ADM.0000000000001267. Epub 2024 Jan 22. J Addict Med. 2024. PMID: 38258865 Clinical Trial.
Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials.
Bakouni H, Sharafi H, Bahremand A, Drouin S, Ziegler D, Bach P, Le Foll B, Schütz CG, Tardelli V, Ezard N, Siefried K, Jutras-Aswad D. Bakouni H, et al. Drug Alcohol Depend. 2023 Dec 1;253:111018. doi: 10.1016/j.drugalcdep.2023.111018. Epub 2023 Nov 4. Drug Alcohol Depend. 2023. PMID: 37979478 Review.
Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
Bakouni H, Sharafi H, Drouin S, Fortin R, Marsan S, Brissette S, Socias ME, Le Foll B, Lim R, Jutras-Aswad D. Bakouni H, et al. Can J Psychiatry. 2024 Apr;69(4):252-263. doi: 10.1177/07067437231210796. Epub 2023 Oct 30. Can J Psychiatry. 2024. PMID: 37899716 Clinical Trial.
13 results